ПОБОЧНОЕ ДЕЙСТВИЕ АМИОДАРОНА НА КОЖУ


Цитировать

Полный текст

Об авторах

Д И Рейнгардене

Каунасский медицинский университет, Литва

Каунасский медицинский университет, Литва

Список литературы

  1. Jafari-Fesharaki M., Scheinman M. M. Adverse effects of amiodarone. Pacing Clin. Electrophysiol. 1998; 21 (1): 108-120.
  2. Ceremuzynski L., Kleczar E., Kneminska-Pakula M. et al. Effect of amiodarone on mortality after myocardial infarction: a double - blind, placebo - controlled, pilot study. J. Am. Coll. Cardiol. 1992; 20: 1056-1062.
  3. Lee K. L., Tai Y. T. Long - term low - dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmia: efficacy and safety. Clin. Cardiol. 1997; 20 (4): 372-377.
  4. Yazigi A., Rahbani P., Zeid H. A. et al. Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. J. Cardiothorac. Vase. Anesth. 2002; 16 (5): 603-606.
  5. Nicklas J. M., McKenna W. J., Stewart R. A. Prospective, double - blind, placebo - controlled trial of low- dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am. Heart J. 1991; 122: 1016-1021.
  6. Naccarelli G. V., Wolbrette D. L., Patel H. M., Luck J. С. Amiodarone: clinical trials. Curr. Opin. Cardiol. 2000; 15 (1): 64- 72.
  7. Kerin N. Z., Faitel K., Kerin I. A. et al. Efficacy of low - dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type IA antiarrhythmic drugs. Am. J. Ther. 2000; 7 (4): 245-250.
  8. Kowey P. R., Frichling T. D., Marinchak R. A. et al. Safety and efficacy of amiodarone. The low - dose perspective. Chest 1988; 93: 54-59.
  9. Rappersberger K., Honigsmann H., Ortel B. et al. Photosensitivity and hyperpigmentation in amiodarone - treated patients: incidence, time course, and recovery. J. Invest. Dermatol. 1989; 93: 201-209.
  10. Vorperian V. R., Havighurst T. C., Miller S., January С. Т. Adverse effects of low dose amiodarone: a meta - analysis. J.Am. Coll. Cardiol. 1997; 30 (3): 791-798.
  11. Cairns J. A., Connolly S. J., Gent M., Roberts R. Post - myocardial infarction mortality in patients with ventricular premature depolarization: Canadian myocardial infarction amiodarone trial pilot study. Circulation 1991; 84: 550-557.
  12. Drug - induced cutaneous photosensitivity: some drugs warrant routine precautions. Prescrire Int. 2000; 9 (48): 117-122.
  13. Bosca F., Miranda M. A. Photosensitizing drugs containing the benzophenone chromophore. J. Photochem. Photobiol. В 1998; 43: 1-26.
  14. Auer J., Berent R., Eber B. Amiodarone in the prevention and treatment of arrhythmia. Curr. Opin. Invest. Drugs 2002; 3 (7): 1037-1044.
  15. White C. M., Giri S., Tsikouris J. P. et al. A comparison of two individual amiodarone regimens to placebo in open heart surgery patients. Ann. Thorac. Surg. 2002; 74 (1): 69-74.
  16. Hein L. Amiodarone. Dtsch. Med. Wschr. 2001; 126 (21): 625-626.
  17. Goldschlager N., Epstein A. E., Naccarelli G. et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of pacing and electrophysiology. Arch. Intern. Med. 2000; 160 (12): 1741-1748.
  18. Murphy M. Т., Wilkoff B. L. What internists should know about amiodarone. Cleveland Clin. J. Med. 1998; 65 (3): 159- 166
  19. Rokicki W., Durmala J., Nowakowska E. Amiodarone for long term treatment of arrhythmia in children. Wiad. Lek. 2001; 54 (1-2): 45-50.
  20. Crystal E., Kahn S., Roberts R. et al. Long - term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). J. Thorac. Cardiovasc. Surg. 2003; 125 (3): 633-637.
  21. Brendorp В., Pedersen O., Torp-Pedersen C. et al. A benefitrisk assessment of class III antiarrhythmic agents. Drug Saf. 2002; 25 (12): 847-865.
  22. Lowe N. J. Photosensitivity. Medicine 1988; 49: 2022-2024.
  23. Singh B. N. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin. Cardiol. 1997; 20 (7): 608-618.
  24. Singh S. N., Fletcher R. D., Fisher S. G. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 1995; 333: 77-82.
  25. Zachary С. В., Slater D. N., Holt D. W. et al. The pathogenesis of amiodarone - induced pigmentation and photosensitivity.Br. J. Dermatol. 1984; 110: 451-456.
  26. Sirajudeen K. N., Gurumoorthy P., Devaraj H., Devaraj S. N. Amiodarone - induced phospholipidosis: an in vivo (14C) - acetate uptake study in rat. Drag Chem. Toxicol. 2002; 25 (3): 247-254.
  27. Bianco A. C., Salvatore D., Bereben B. et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 2002; 23 (1): 38-89.
  28. Sivaram С. A., Beckman K. J. Images in clinical medicine. Amiodarone - induced skin discoloration. N. Engl. J. Med. 1997; 337 (25): 1813.
  29. Miller R. A. W., McDonal A. T. Dermal lipofuscinosis associated with amiodarone therapy. Arch. Dermatol. 1984; 120: 646-649.
  30. Wohlrab J., Fischer M., Stoldt G., Marsch W. С 52-year old patient with skin discoloration. Internist (Berl.) 2001; 49 (9): 1256-1260.
  31. Haas N., Schadendorf D., Hermes В., Henz В. М. Hypomelanosis due to block of melanosomal maturation in amiodaroneinduced hyperpigmentation. Arch. Dermatol. 2001; 137 (4): 513-514.
  32. Dereure O. Drug - induced skin pigmentation. Epidemiology, diagnosis and treatment. Am. J. Clin. Dermatol. 2001; 2 (4): 253-262.
  33. Klein A. D., Pardo R. J., Gould E., Kerdel F. Blue - grey discoloration of the face. Amiodarone - induced cutaneous hyperpigmentation. Arch. Dermatol. 1989; 125: 417, 420-421.
  34. Bahadir S., Apaydin R., Cobanoilu U. et al. Amiodarone pigmentation, eye and thyroid alterations. J. Eur. Acad. Dermatol. Venereol. 2000; 14 (3): 194-195.
  35. Kundu A. K. Amiodarone - induced systemic lupus erythematosus. J. Assoc. Physicians India 2003; 51: 216-217.
  36. Yung A., Agnew K., Snow J., Oliver F. Two unusual cases of toxic epidermal necrolysis. Austral. J. Dermatol. 2002; 43: 35- 38.
  37. Mendez M., Parere V., Salamanca R. E., Batlle A. Amiodarone is a pharmacologically safe drug for porphyrias. Gen. Pharmacol. 1999; 32: 259-263.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2004

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах